CJEU clarifies ‘basic patent’ meaning in SPC dispute
Earlier today, the Court of Justice of the European Union (CJEU) clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of regulation 469/2009 (the SPC regulation).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
30 April 2020 The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.
6 November 2018 Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
9 August 2018 A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.